The worldwide insulin market is currently monopolized by three major companies, and high costs pose a treatment barrier for many people with diabetes. In fact, of the 100 million people living with diabetes, it is estimated that half find … Read More
The FDA has given its approval to LUSDUNA Nexvue, an injectable basal insulin manufactured by Merck. This insulin is a biologic insulin glargine. The FDA’s approval is only tentative, however, because Merck is currently in the middle of a … Read More
The elderly often have some difficultly in successfully injecting insulin themselves. However, a cognitive test that asks patients to recall animal names has proven to be a strong indicator in showing which patients can successfully perform… Read More
Lyon and Indianapolis, May 31, 2016 – Adocia (Euronext Paris: ADOC) and Eli Lilly and Company (NYSE: LLY) announced today positive topline results from a Phase 1 clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation
A recent study has found that insulin treatment is not responsible for the poorer health outcomes after stenting in patients with type 2 diabetes. However, it was suggested that everolimus-eluting stents might be a better choice for patients… Read More
Listen to today’s podcast here!
New research shows that women who are taking insulin for diabetes treatment are at a higher risk of dense breasts. Researchers from the University of Southern Denmark in Esbjerg are responsible for the… Read More
Researchers recently completed a study to find out how the risk of fracture differed with the type of insulin therapy used by people with type 2 diabetes. While it is known that there is an increased risk of fracture associated with type 2 diabetes,… Read More